Fidelity International’s Mersana Therapeutics MRSN Stock Holding History

Fidelity International’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,097	Closed	-$712K	–	870
2021 Q2	$712K	Hold	2,097	–	–	﹤0.01%	765
2021 Q1	$848K	Buy	+2,097	New	+$1.02M	﹤0.01%	729
2020 Q3	–	Sell	-13	Closed	-$8K	–	971
2020 Q2	$8K	Buy	+13	New	+$4.44K	﹤0.01%	745
2019 Q1	–	Sell	-14,202	Closed	-$1.45M	–	910
2018 Q4	$1.45M	Hold	14,202	–	–	﹤0.01%	593
2018 Q3	$3.55M	Hold	14,202	–	–	0.01%	578
2018 Q2	$6.34M	Sell	14,202 -4,734	-25%	-$2.08M	0.01%	531
2018 Q1	$7.47M	Hold	18,936	–	–	0.02%	377
2017 Q4	$7.78M	Buy	+18,936	New	+$8.26M	0.02%	373

Other funds holding MRSN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity International's MRSN Position: Q3 2021 in Review

Fidelity International sold out of Mersana Therapeutics (MRSN) in Q3 2021, closing a stake of 2,097 shares — an estimated $712K sold.

Fidelity International first reported a position in MRSN in Q4 2017 and held it in 8 quarters. The position peaked at $7.78M in Q4 2017. 109 funds tracked by Wall St. Rank hold MRSN as of Q3 2021.

Fidelity International reported no remaining Mersana Therapeutics position as of Q3 2021 after selling out during the quarter.
Fidelity International sold 2,097 Mersana Therapeutics shares in Q3 2021, an estimated $712K.
Fidelity International first reported a position in Mersana Therapeutics in Q4 2017 and held it in 8 quarters.
Fidelity International's Mersana Therapeutics position peaked at $7.78M in Q4 2017.
109 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2021.

Based on Fidelity International's 13F filing for Q3 2021, filed 15 Nov 2021.